About this trial
Prematurity remains the main cause of death and serious health problems in new-borns. Besides the need for hospitalization and medical interventions in the first weeks or months of the new-borns' life, prematurity can cause long-lasting health problems (e.g. multiple hospital admissions, developmental delay, learning difficulties, motor delay, hearing or eye problems, ...). Moreover, prematurity places an enormous economic burden on the society. Aside from the medical problems and the financial cost, the emotional stress and psychological impact on the parents, siblings and other family members should not be underestimated.
Previous preterm delivery (before 37 weeks of pregnancy) increases the risk for recurrent preterm delivery in a subsequent pregnancy. Therefore, these women should be considered as 'high risk' for preterm birth.
Infections ascending from the vagina may be an important cause of preterm delivery in certain cases. Some women have an abnormal vaginal microbiome and are therefore at risk for infections and preterm birth. On the other hand, the vaginal flora is more stable and resistant to infections in healthy pregnant women who deliver at term (after 37 weeks of gestation).
Synbiotics are a mixture containing probiotics and prebiotics. Probiotics are living bacteria with potential beneficial effects that can be used safely in pregnancy, while prebiotics are consumed by the bacteria. It is known that probiotics, when used for a long period of time, can maintain a healthy and stable vaginal flora that may protect against infections. In this study, pregnant patients with a history of preterm birth will be included in the first trimester of pregnancy to start with synbiotics or placebo. The investigators will examine the effect of synbiotics on the vaginal flora and on the pregnancy duration. The hypothesis is that synbiotics, when started early in the pregnancy, can change the disturbed vaginal flora into a stable micro-environment.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Signed written informed consent must be obtained before any study assessment is performed;
18 years of age or older;
Singleton pregnancy;
Pregnancy consultation between 8 and 10 weeks gestation.
Disqualifiers
Patients who are already using pro-, pre- or synbiotics and not willing to stop
Multiple pregnancy
Need for primary (type 1) cerclage
Inflammatory bowel disease
Trial design
Parallel
Treatments tested in this trial
Synbiotics
Other interventionOral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
Placebo
Other interventionMatching placebo
Treatment groups
Trial outcomes
Primary outcomes
Gestational age at delivery
Secondary outcomes
Incidence of PTB, defined as GA at delivery < 37 weeks
Proportion of PTB in different categories
* of patients that deliver \< 28 weeks: extreme PTB * of patients that deliver from 28 until 37 weeks: very PTB * of patients that deliver from 32 until 37 weeks: moderate to late PTB
PPROM
Incidence
PPROM
Gestational age at PPROM
Other outcomes
Effect of antibiotics on the vaginal microbiome
When the patient is admitted in case the pregnancy was complicated with PPROM
Effect on the gastrointestinal microbiome of the neonate in case of PPROM
When the neonate is born after a pregnancy complicated with PPROM
Placental microbiome in case of preterm birth
In case the pregnancy was complicated with preterm birth (delivery before 37 weeks of gestation)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Ziekenhuis Oost-Limburg
Lead sponsor
Federaal Kenniscentrum voor Gezondheidszorg, Belgium
Collaborator